Skip to main content
Feedback to SSRN
Feedback
(required)
Email
(required)
Submit
Kai-Xin Du
Nanjing Medical University
Learn more about SSRN Profiles
SCHOLARLY PAPERS
1
DOWNLOADS
82
TOTAL CITATIONS
0
Feedback
Scholarly Papers (1)
Sort by:
Paper Title, A-Z
Paper Title, Z-A
Author Name, A-Z
Author Name, Z-A
Date Posted, Ascending
Date Posted, Descending
Downloads, Ascending
Downloads, Descending
Citations, Ascending
Citations, Descending
Actions:
Email selected abstracts
View:
Selected
Original List
All Versions
Hide All Versions
All Abstracts
Hide All Abstracts
(Rank)
1.
Penpulimab in Combination with Lenalidomide and R-GemOx Regimen (R2-GemOx-PD1i) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Multicentre, Single-Arm, Phase 2 Trial
Number of pages: 27
Posted: 01 May 2025
Jin-Hua Liang
,
Hua Yin
,
Wei-Ying Gu
,
Tong-Yao Xing
,
Qing-Shu Zeng
, Kai-Xin Du,
Luthuli Sibusiso
,
Jia-Zhu Wu
,
Yue Li
,
Fei Wang
,
Rui Gao
,
Jian-Yong Li
,
Hao-Rui Shen
,
Li Wang
and
Wei Xu
Nanjing Medical University - Department of Hematology, Nanjing Medical University - Department of Hematology, Nanjing Medical University, Nanjing Medical University, Anhui Medical University, Nanjing Medical University, Nanjing Medical University, The First Affiliated Hospital of Nanjing Medical University - Department of Hematology, Nanjing Medical University - Department of Hematology, Nanjing Medical University, Nanjing Medical University, The First Affiliated Hospital of Nanjing Medical University - Department of Hematology, Nanjing Medical University - Department of Hematology, Nanjing Medical University - Department of Hematology and The First Affiliated Hospital of Nanjing Medical University - Department of Hematology
Downloads
82
(790,029)
View PDF
Download
Abstract:
DLBCL, penpulimab, lenalidomide, R-GemOx, efficacy, relapsed, refractory
Feedback